Antibiotics for common sore throats have very limited effect on Strep spread
en-GBde-DEes-ESfr-FR

Antibiotics for common sore throats have very limited effect on Strep spread


Antibiotics for sore throats have hardly any preventive effect against serious streptococcal infections in the population, according to a study from the University of Gothenburg. Instead, healthcare needs to quickly recognize warning signs of a serious infection.
Group A streptococcus (GAS) is a common bacterium that can cause invasive GAS infection (iGAS) if the bacteria enter, for example, the blood or lungs. The condition is potentially life-threatening and relatively uncommon, but its incidence has increased in recent years in several countries.
Since uncomplicated sore throats can sometimes develop into iGAS, or infect others in the community, early antibiotic treatment is often debated as part of preventive measures.
However, the researchers behind the current study, published in the International Journal of Infectious Diseases, show that prescribing antibiotics for uncomplicated acute sore throats, with the aim of preventing iGAS, has very limited effect at the population level.
“The intention to prevent iGAS infections should no longer be used as an argument for treating common throat infections with antibiotics, that strategy is greatly overrated”, says Ronny Gunnarsson, lead author of the study, Family Physician and Professor Emeritus at the University of Gothenburg.
Minimal preventive effect
By combining scientific evidence with epidemiological data for the entire Swedish population in 2024, the researchers have calculated how different strategies affect the incidence of iGAS.
The results show that even in an extreme scenario – where all patients seeking care for a sore throat are tested and treated if they carry the bacteria – at most 6.7 percent of iGAS cases could be prevented in children and 2.8 percent in adults.
If current Swedish guidelines are followed instead, where testing is only done if the patient meets three to four specific symptoms according to the Centor criteria, the preventive effect is a maximum of 1.6 percent in children and 1.2 percent in adults.
“The proportion of iGAS cases that can actually be prevented with antibiotics is much smaller than one might think. Our calculations show that throat swabs must be taken from between 45,000 and 110,000 patients, and up to 110,000 antibiotic prescriptions must be written, just to prevent a single case of iGAS”, says Ronny Gunnarsson.
Contagious before the healthcare visit
The researchers point to several reasons why antibiotics are ineffective against iGAS at the population level. Most people who get a sore throat never contact a health care center. Those who do usually seek care on the third day of illness or later, when they have already passed their most contagious period.
In addition, 15–25 percent of iGAS patients are infected by asymptomatic carriers, i.e. people who feel completely healthy and who therefore should not have antibiotics. The study concludes that a lowered threshold for testing and treating sore throats would lead to major negative consequences for the primary care.
“Broadening the criteria for sampling and antibiotic treatment would mean an enormous burden for primary care and crowd out other patient groups, not to mention the risk of side effects from antibiotics”, says Ronny Gunnarsson, and continues:
“Instead of prescribing antibiotics for uncomplicated sore throats, healthcare should focus on quickly recognizing early warning signs of serious infection, and in the long term await a safe and effective vaccine against streptococci.”
Antibiotics for the uncomplicated acute sore throat to prevent invasive group A Streptococcus (iGAS) - a critical analysis of current evidence
Ronny Gunnarsson, Erik Wiezell, Carl Wikberg, Pär-Daniel Sundvall, Karin Rystedt
International Journal of Infectious Diseases
https://doi.org/10.1016/j.ijid.2026.108818
Fichiers joints
  • Prof. Ronny Gunnarsson, Sahlgrenska Academy at the University of Gothenburg (photo: Pernilla Häyhänen)
Regions: Europe, Sweden
Keywords: Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Témoignages

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Nous travaillons en étroite collaboration avec...


  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement